<- Go Home
MyoKardia, Inc.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and sells targeted therapies for the treatment of serious cardiovascular diseases. The company was incorporated in 2012 and is based in Brisbane, California. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Market Cap
$12.0B
Volume
486.7K
Cash and Equivalents
$675.5M
EBITDA
-$280.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$200.2M
Profit Margin
N/A
52 Week High
$225.00
52 Week Low
$42.65
Dividend
N/A
Price / Book Value
14.19
Price / Earnings
-39.77
Price / Tangible Book Value
14.19
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$283.2M
Return on Equity
42.70%
Return on Assets
-23.07
Cash and Short Term Investments
$895.9M
Debt
$51.6M
Equity
$845.0M
Revenue
N/A
Unlevered FCF
-$187.8M
Sector
Pharmaceuticals
Category
N/A